Nama's AI scorecard currently rates Fortrea Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is FTRE's P/E ratio?

Fortrea trades at a trailing price-to-earnings ratio of 28.9.

When does FTRE report earnings?

Fortrea's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.20.

What is the FTRE price target?

The median analyst price target from 12 analysts is $25.50, with a range of $13.50 – $29.00.

Is FTRE Shariah compliant?

Nama's AAOIFI-style screen reads Fortrea as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Fortrea (FTRE)

Healthcare · Biotechnology · NASDAQ

Fortrea (FTRE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.12B, a trailing price-to-earnings ratio of 28.9 and a free-cash-flow yield of 4.4%. Over the most recent reported fiscal year, revenue grew 1.0% and free cash flow per share fell 63.5%. Nama's AI scorecard rates it Hold, 4.7 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.7/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +86.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-46.5%

How far the last close sits under the highest price of the past five years.

Market cap	$2.12B
Trailing P/E	28.9
Price / book	4.0
Price / sales	0.8
FCF yield	4.4%
Dividend yield	—
Gross margin	19.3%
Operating margin	1.0%
Net margin	-3.2%
Revenue growth (YoY)	+1.0%
Revenue growth (3-yr annual)	-1.4%
EPS growth (YoY)	+23.5%
FCF/share growth (YoY)	-63.5%
Beta	1.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

FTRE earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.20). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.28	$0.22	+27.3%	$691.50M
Q2 2026	Jul 29, 2026	$0.23	$0.18	+27.8%	$678.20M
Q1 2026	May 5, 2026	$0.16	$0.05	+220.0%	$636.50M
Q4 2025	Feb 26, 2026	$0.09	$0.16	-43.8%	$660.50M

FTRE analyst price target

Median target $25.50 from 12 analysts, ranging $13.50 – $29.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live FTRE data on Nama Insights →

Recent Congressional trades

Fortrea trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
James French Hill	House	Sell	$1,001 - $15,000	Jul 24, 2025

FTRE FAQ

Is FTRE a buy?: Nama's AI scorecard currently rates Fortrea Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is FTRE's P/E ratio?: Fortrea trades at a trailing price-to-earnings ratio of 28.9.
When does FTRE report earnings?: Fortrea's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.20.
What is the FTRE price target?: The median analyst price target from 12 analysts is $25.50, with a range of $13.50 – $29.00.
Is FTRE Shariah compliant?: Nama's AAOIFI-style screen reads Fortrea as Not Shariah Compliant. At least one of the three ratios or the industry test failed.